Hormone Replacement Therapy Linked to Lower Dementia Risk in UK Study

What the UK Biobank Hormone Replacement Therapy Study Observed

Women who used hormone replacement therapy (HRT) for at least one year had a 10 percent lower relative risk of dementia compared to nonusers. Researchers analyzed medical records from 183,450 postmenopausal women in the UK Biobank over an average follow-up period of 13.3 years. During that observation window, 3,948 participants received a dementia diagnosis, including 1,993 cases of Alzheimer's disease.

The risk reduction remained apparent after adjustments for age, education, blood pressure, diabetes, smoking, and deprivation. However, the observational design means the data shows a correlation rather than proof of direct protection.

Why Surgical Menopause Showed a Larger Association

The reduction in dementia diagnosis was concentrated among women who had undergone surgical menopause. In that surgical subgroup, hormone therapy use was associated with a 26 percent lower relative risk of dementia. Among women who experienced natural menopause, researchers observed no statistically clear association.

The surgical menopause category combined procedures with very different hormonal outcomes. It grouped women who had a hysterectomy together with women who had both ovaries removed. Removing both ovaries triggers an abrupt loss of estrogen production, whereas womb removal alone does not stop ovarian hormone generation.

• 10 percent lower relative risk of dementia across all users with at least one year on HRT.
• 26 percent lower relative risk among women categorized under surgical menopause.
• No statistically clear association identified among women who underwent natural menopause.

Healthy User Bias and Missing Formulation Details

Observational datasets frequently reflect preexisting health advantages among women who receive hormone prescriptions. An earlier investigation showed that women who later initiated hormone replacement therapy were already healthier eight years before starting care. Those patients displayed lower blood pressure, lower diabetes risk, higher activity levels, and higher education levels, all of which correlate independently with lower dementia rates.

The analysis also lacked granular records on specific hormone formulations and delivery methods. The researchers could not separate estrogen-only treatments from combined regimens that add a progestogen to protect the uterine lining. A previous review of national registries noted a small increase in Alzheimer's risk with prolonged combined hormone therapy, an effect absent with estrogen alone.

Timing of Treatment and Genetic Risk Factors

Treatment timing appeared relevant, with lower dementia diagnosis rates appearing primarily among women who began therapy between their late 40s and mid-50s. The statistical pattern was less convincing for women who initiated treatment at younger ages. This difference complicates arguments that replacing hormones as early as possible provides broad protection.

Investigators also evaluated whether carrying the APOE ε4 genetic variant altered the outcome. While the association appeared stronger in carriers during preliminary observation, statistical testing failed to show that the therapy affected them differently from noncarriers.

What This Means for Evaluating Hormone Replacement Therapy

Patients considering hormone therapy should discuss the specific indications and individual risk profiles directly with their clinician. Other analyses drawn from the same UK Biobank registry have yielded conflicting conclusions, including one report that linked lifetime use to higher dementia risk in women experiencing natural menopause after age 50.

Single observational studies cannot resolve whether hormone replacement therapy actively prevents cognitive decline. Treatment decisions rely on established medical reasons, such as managing severe menopausal symptoms or addressing surgical removal of the ovaries.